Amedeo Smart

Free Medical Literature Service


 

Amedeo

Diabetes

  Free Subscription

Articles published in
Kidney Int
    July 2021
  1. HUANG H, Parikh SM
    Skimming the fat in diabetic kidney disease: KIM-1 and tubular fatty acid uptake.
    Kidney Int. 2021 Jul 20. pii: S0085-2538(21)00688.
    >> Share

  2. FANG Y, Chen B, Gong AY, Malhotra D, et al
    The ketone body beta-hydroxybutyrate mitigates the senescence response of glomerular podocytes to diabetic insults.
    Kidney Int. 2021 Jul 8. pii: S0085-2538(21)00665.
    >> Share

    May 2021
  3. KE G, Chen X, Liao R, Xu L, et al
    Receptor activator of NF-kappaB mediates podocyte injury in diabetic nephropathy.
    Kidney Int. 2021 May 27. pii: S0085-2538(21)00503.
    >> Share

  4. DOU L, Burtey S
    Reversing endothelial dysfunction with empagliflozin to improve cardiomyocyte function in cardiorenal syndrome.
    Kidney Int. 2021;99:1062-1064.
    >> Share

    April 2021
  5. WHEELER DC, Toto RD, Stefansson BV, Jongs N, et al
    A pre-specified analysis of the DAPA-CKD trial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
    Kidney Int. 2021 Apr 17. pii: S0085-2538(21)00396.
    >> Share

  6. LAVILLE M
    Back off to better blow up: acute GFR decrease at SGLT-2 inhibitor initiation.
    Kidney Int. 2021;99:814-816.
    >> Share

  7. OSHIMA M, Jardine MJ, Agarwal R, Bakris G, et al
    Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
    Kidney Int. 2021;99:999-1009.
    >> Share

    March 2021
  8. WU L, Liu C, Chang DY, Zhan R, et al
    Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy.
    Kidney Int. 2021 Mar 3. pii: S0085-2538(21)00267.
    >> Share

  9. VAN RAALTE DH, Bjornstad P, Heerspink HJL, Persson F, et al
    Importance of standardizing renal outcomes in clinical trials: illustration by recent sodium glucose cotransporter 2 inhibitor studies.
    Kidney Int. 2021;99:768-770.
    >> Share

  10. GREGG LP, Navaneethan SD
    Early eGFR decline after SGLT2i initiation: knowns and unknowns.
    Kidney Int. 2021;99:548-550.
    >> Share

  11. KRAUS BJ, Weir MR, Bakris GL, Mattheus M, et al
    Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
    Kidney Int. 2021;99:750-762.
    >> Share

    February 2021
  12. DRUEKE TB
    Cardiovascular and renal risk reduction in type 2 diabetes---which choice?
    Kidney Int. 2021;99:322-323.
    >> Share

  13. NANGAKU M, Wanner C
    Not only incretins for diabetic kidney disease-beneficial effects by DPP-4 inhibitors.
    Kidney Int. 2021;99:318-322.
    >> Share

  14. MANN JFE, Muskiet MHA
    Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists.
    Kidney Int. 2021;99:314-318.
    >> Share

  15. TUTTLE KR, Cherney DZI
    Therapeutic transformation for diabetic kidney disease.
    Kidney Int. 2021;99:301-303.
    >> Share

  16. HEERSPINK HJL, Kohan DE, de Zeeuw D
    New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.
    Kidney Int. 2021;99:346-349.
    >> Share

    January 2021
  17. FLOEGE J, Johnson RJ
    Hyperuricemia and progression of chronic kidney disease: to treat or not to treat?
    Kidney Int. 2021;99:14-16.
    >> Share

    December 2020
  18. FENG J, Li B, Wang X, Li H, et al
    Low expression of HIV genes in podocytes accelerates the progression of diabetic kidney disease in mice.
    Kidney Int. 2020 Dec 22. pii: S0085-2538(20)31531.
    >> Share

    November 2020
  19. MEYER-SCHWESINGER C
    The ins-and-outs of podocyte lipid metabolism.
    Kidney Int. 2020;98:1087-1090.
    >> Share

  20. HANNA RM, Rhee CM, Kalantar-Zadeh K
    Metformin in chronic kidney disease: a strong dose of caution.
    Kidney Int. 2020;98:1101-1105.
    >> Share

  21. DE BROE ME, Jouret F
    Does metformin do more benefit or harm in chronic kidney disease patients?
    Kidney Int. 2020;98:1098-1101.
    >> Share

    October 2020
  22. MENON R, Otto EA, Sealfon R, Nair V, et al
    SARS-CoV-2 receptor networks in diabetic and COVID-19 associated kidney disease.
    Kidney Int. 2020 Oct 7. pii: S0085-2538(20)31113.
    >> Share


  23. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease.
    Kidney Int. 2020;98.
    >> Share

    September 2020
  24. SINGH N, Tandukar S, Zibari G, Naseer MS, et al
    Successful Simultaneous Pancreas and Kidney Transplant in a Patient Post-COVID-19 Infection.
    Kidney Int. 2020 Sep 15. pii: S0085-2538(20)31079.
    >> Share

  25. UEKI K, Sasako T, Okazaki Y, Miyake K, et al
    Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes.
    Kidney Int. 2020 Sep 3. pii: S0085-2538(20)30974.
    >> Share

  26. NANGAKU M
    Schlondorff and Lee revealed crosstalk between glomerular cells and a role of BAMBI in diabetic kidney disease.
    Kidney Int. 2020;98:539-541.
    >> Share

    July 2020
  27. LIU X, Ducasa GM, Mallela SK, Kim JJ, et al
    Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport Syndrome.
    Kidney Int. 2020 Jul 30. pii: S0085-2538(20)30837.
    >> Share

  28. IHARA K, Skupien J, Krolewski B, Md Dom ZI, et al
    A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders.
    Kidney Int. 2020 Jul 24. pii: S0085-2538(20)30834.
    >> Share

  29. DE BOER IH, Caramori ML, Chan JCN, Heerspink HJL, et al
    TEMPORARY REMOVAL: Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: Evidence-based advances in monitoring and treatment.
    Kidney Int. 2020 Jul 10. pii: S0085-2538(20)30798.
    >> Share

  30. NANGAKU M
    Founding papers of current nephrology: from acute kidney injury to diabetic kidney disease.
    Kidney Int. 2020;98:6-9.
    >> Share

    May 2020
  31. LI J, Neal B, Perkovic V, de Zeeuw D, et al
    Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.
    Kidney Int. 2020 May 26. pii: S0085-2538(20)30565.
    >> Share

  32. FORBES JM
    Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?
    Kidney Int. 2020;97:855-857.
    >> Share


  33. Corrigendum to "van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients
    Kidney Int. 2020;97:1061.
    >> Share

  34. MCCARTHY KJ
    Syndecan-4: major player or innocent bystander of the endothelial glycocalyx?
    Kidney Int. 2020;97:858-860.
    >> Share

  35. RAMNATH RD, Butler MJ, Foster RR, Satchell SC, et al
    The authors reply.
    Kidney Int. 2020;97:1057-1058.
    >> Share

  36. COMPER WD
    There is little evidence that the endothelial glycocalyx has a specific role in glomerular permeability of albumin.
    Kidney Int. 2020;97:1057.
    >> Share

    April 2020
  37. LAI H, Chen A, Cai H, Fu J, et al
    Podocyte and endothelial-specific elimination of BAMBI identifies differential transforming growth factor-beta pathways contributing to diabetic glomerulopathy.
    Kidney Int. 2020 Apr 26. pii: S0085-2538(20)30429.
    >> Share

  38. HESP AC, Schaub JA, Prasad PV, Vallon V, et al
    The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
    Kidney Int. 2020 Apr 26. pii: S0085-2538(20)30419.
    >> Share

  39. JIA C, Ke-Hong C, Fei X, Huan-Zi D, et al
    Decoy receptor 2 mediation of the senescent phenotype of tubular cells by interacting with peroxiredoxin 1 presents a novel mechanism of renal fibrosis in diabetic nephropathy.
    Kidney Int. 2020 Apr 24. pii: S0085-2538(20)30405.
    >> Share


  40. Corrigendum to "Townsend RR, Guarnieri P, Argyropoulos C, et al.; on behalf of the TRIDENT Study Investigators. Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study." Kidney Int. 2020;97:10-13.
    Kidney Int. 2020;97:809.
    >> Share

  41. VAN BOMMEL EJM, Lytvyn Y, Perkins BA, Soleymanlou N, et al
    Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
    Kidney Int. 2020;97:631-635.
    >> Share

  42. VAN BOMMEL EJM, van Raalte DH
    The authors reply.
    Kidney Int. 2020;97:806.
    >> Share

  43. SOLER MJ, Porrini E, Fernandez-Fernandez B, Ortiz A, et al
    SGLT2i and postglomerular vasodilation.
    Kidney Int. 2020;97:805-806.
    >> Share

    February 2020
  44. BJORNSTAD P, Nehus E, Jenkins T, Mitsnefes M, et al
    Five-year kidney outcomes of bariatric surgery differ in severely obese adolescents and adults with and without type 2 diabetes.
    Kidney Int. 2020 Feb 3. pii: S0085-2538(20)30114.
    >> Share

  45. SUGAHARA M, Tanaka T, Nangaku M
    Modulating the immune system to delay the clinical onset of type 1 diabetes.
    Kidney Int. 2020;97:248-250.
    >> Share

  46. SALEHI T, Coates PT
    Class effect: dapagliflozin reduces cardiovascular and kidney events.
    Kidney Int. 2020;97:246-248.
    >> Share

    January 2020
  47. BJORNSTAD P, Nelson RG, Pavkov ME
    Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?
    Kidney Int. 2020;97:31-33.
    >> Share

  48. LEON-JIMENEZ D, Moreno-Obregon F, Beltran-Romero LM, Miramontes-Gonzalez JP, et al
    Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
    Kidney Int. 2020;97:213.
    >> Share

  49. TOWNSEND RR, Guarnieri P, Argyropoulos C, Blady S, et al
    Rationale and design of the Transformative Research in Diabetic Nephropathy (TRIDENT) Study.
    Kidney Int. 2020;97:10-13.
    >> Share

  50. MAYER GJ, Wanner C, Weir MR, Inzucchi SE, et al
    The authors reply.
    Kidney Int. 2020;97:213-214.
    >> Share

    December 2019
  51. HASEGAWA S, Tanaka T, Saito T, Fukui K, et al
    The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic kidney disease.
    Kidney Int. 2019 Dec 25. pii: S0085-2538(19)31247.
    >> Share

  52. JENSSEN TG
    Prediabetes after kidney transplantation-a reason to worry?
    Kidney Int. 2019;96:1280-1282.
    >> Share

    November 2019
  53. RAMNATH RD, Butler MJ, Newman G, Desideri S, et al
    Blocking matrix metalloproteinase-mediated syndecan-4 shedding restores the endothelial glycocalyx and glomerular filtration barrier function in early diabetic kidney disease.
    Kidney Int. 2019 Nov 2. pii: S0085-2538(19)31110.
    >> Share

    October 2019
  54. LIANG X, Wang P, Chen B, Ge Y, et al
    Glycogen synthase kinase 3beta hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease.
    Kidney Int. 2019 Oct 10. pii: S0085-2538(19)30992.
    >> Share

  55. VAN BOMMEL EJM, Muskiet MHA, van Baar MJB, Tonneijck L, et al
    The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
    Kidney Int. 2019 Oct 10. pii: S0085-2538(19)30991.
    >> Share

  56. ITO M, Nangaku M
    Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
    Kidney Int. 2019;96:823-825.
    >> Share

  57. MARQUEZ A, Batlle D
    Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone?
    Kidney Int. 2019;96:815-817.
    >> Share

  58. NISHI H, Nangaku M
    Podocyte lipotoxicity in diabetic kidney disease.
    Kidney Int. 2019;96:809-812.
    >> Share

    September 2019
  59. VERMA N, Liu M, Ly H, Loria A, et al
    Diabetic microcirculatory disturbances and pathologic erythropoiesis are provoked by deposition of amyloid-forming amylin in red blood cells and capillaries.
    Kidney Int. 2019 Sep 5. pii: S0085-2538(19)30844.
    >> Share

  60. WILLIAMS ME
    Said the glucose sensor to the insulin pump: can glycemic control be improved in hospitalized ESRD patients with diabetes mellitus?
    Kidney Int. 2019;96:540-542.
    >> Share

    August 2019
  61. KAMMER M, Heinzel A, Willency JA, Duffin KL, et al
    Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes.
    Kidney Int. 2019 Aug 30. pii: S0085-2538(19)30841.
    >> Share

  62. PORRINI E, Diaz JM, Moreso F, Lauzurrica R, et al
    Prediabetes is a risk factor for cardiovascular disease following renal transplantation.
    Kidney Int. 2019 Aug 14. pii: S0085-2538(19)30810.
    >> Share

  63. VAN BAAR MJB, Scholtes RA, van Raalte DH
    SGLT2 inhibitors' interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn.
    Kidney Int. 2019;96:283-286.
    >> Share

    July 2019
  64. KANDA E, Nangaku M
    Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
    Kidney Int. 2019;96:8-10.
    >> Share

    June 2019
  65. ZHANG D, Gava AL, Van Krieken R, Mehta N, et al
    The caveolin-1 regulated protein follistatin protects against diabetic kidney disease.
    Kidney Int. 2019 Jun 17. pii: S0085-2538(19)30618.
    >> Share

    May 2019
  66. BALMER LA, Whiting R, Rudnicka C, Gallo LA, et al
    Genetic characterization of early renal changes in a novel mouse model of diabetic kidney disease.
    Kidney Int. 2019 May 30. pii: S0085-2538(19)30510.
    >> Share

  67. KODAMA Y, Hyodo F, Yamato M, Yasukawa K, et al
    Dynamic nuclear polarization magnetic resonance imaging and the oxygen-sensitive paramagnetic agent OX63 provide a noninvasive quantitative evaluation of kidney hypoxia in diabetic mice.
    Kidney Int. 2019 May 24. pii: S0085-2538(19)30515.
    >> Share

  68. ROSSING P, Block GA, Chin MP, Goldsberry A, et al
    Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
    Kidney Int. 2019 May 16. pii: S0085-2538(19)30503.
    >> Share

  69. CHO ME, Hansen JL, Peters CB, Cheung AK, et al
    An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease.
    Kidney Int. 2019 May 15. pii: S0085-2538(19)30506.
    >> Share

  70. CASSIS P, Locatelli M, Corna D, Villa S, et al
    Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positive add-on effect in experimental diabetic nephropathy.
    Kidney Int. 2019 May 10. pii: S0085-2538(19)30486.
    >> Share

    April 2019
  71. BARBOUR S, Djurdjev O, Gill JS, Dong JJ, et al
    A propensity score matched analysis shows no adverse effect of early steroid withdrawal in non-diabetic kidney transplant recipients with and without glomerulonephritis.
    Kidney Int. 2019 Apr 1. pii: S0085-2538(19)30388.
    >> Share

    March 2019
  72. MAYER GJ, Wanner C, Weir MR, Inzucchi SE, et al
    Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
    Kidney Int. 2019 Mar 21. pii: S0085-2538(19)30317.
    >> Share

  73. BALLY L, Gubler P, Thabit H, Hartnell S, et al
    Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis.
    Kidney Int. 2019 Mar 20. pii: S0085-2538(19)30322.
    >> Share

  74. LAVOZ C, Matus YS, Orejudo M, Carpio JD, et al
    Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy.
    Kidney Int. 2019 Mar 8. pii: S0085-2538(19)30124.
    >> Share

  75. CHEN G, Chen H, Ren S, Xia M, et al
    Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease.
    Kidney Int. 2019 Mar 7. pii: S0085-2538(19)30273.
    >> Share

  76. SUNG CC, Chen L, Limbutara K, Jung HJ, et al
    RNA-Seq and protein mass spectrometry in microdissected kidney tubules reveal signaling processes initiating lithium-induced nephrogenic diabetes insipidus.
    Kidney Int. 2019 Mar 4. pii: S0085-2538(19)30267.
    >> Share

    February 2019
  77. XU H, Kuja-Halkola R, Chen X, Magnusson PKE, et al
    Higher body mass index is associated with incident diabetes and chronic kidney disease independent of genetic confounding.
    Kidney Int. 2019 Feb 27. pii: S0085-2538(19)30047.
    >> Share

  78. CHEN X, Han Y, Gao P, Yang M, et al
    Disulfide-bond A oxidoreductase-like protein protects against ectopic fat deposition and lipid-related kidney damage in diabetic nephropathy.
    Kidney Int. 2019 Feb 12. pii: S0085-2538(18)30899.
    >> Share

  79. STARUSCHENKO A
    TRPC6 in diabetic kidney disease: good guy or bad guy?
    Kidney Int. 2019;95:256-258.
    >> Share

    January 2019
  80. CANI PD
    Targeting gut microbiota with a complex mix of dietary fibers improves metabolic diseases.
    Kidney Int. 2019;95:14-16.
    >> Share

    December 2018
  81. CHAUHAN K, Verghese DA, Rao V, Chan L, et al
    Plasma endostatin predicts kidney outcomes in patients with type 2 diabetes.
    Kidney Int. 2018 Dec 20. pii: S0085-2538(18)30772.
    >> Share

  82. HIRAKAWA Y, Nangaku M
    Targeting oxidative stress in diabetic kidney disease: a novel drug in an old pathway.
    Kidney Int. 2018;94:1038-1039.
    >> Share

    November 2018
  83. JIANG G, Luk AOY, Tam CHT, Xie F, et al
    Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with Type 2 diabetes.
    Kidney Int. 2018 Nov 2. pii: S0085-2538(18)30629.
    >> Share

    September 2018
  84. MICAKOVIC T, Papagiannarou S, Clark E, Kuzay Y, et al
    The angiotensin II type 2 receptors protect renal tubule mitochondria in early stages of diabetes mellitus.
    Kidney Int. 2018 Sep 3. pii: S0085-2538(18)30442.
    >> Share

    July 2018
  85. TANAKA S, Sugiura Y, Saito H, Sugahara M, et al
    Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
    Kidney Int. 2018 Jul 13. pii: S0085-2538(18)30353.
    >> Share

    June 2018
  86. BOMSZTYK K, Denisenko O, Wang Y
    DNA methylation yields epigenetic clues into the diabetic nephropathy of Pima Indians.
    Kidney Int. 2018;93:1272-1275.
    >> Share

    May 2018
  87. FU J, Wei C, Zhang W, Schlondorff D, et al
    Gene expression profiles of glomerular endothelial cells support their role in the glomerulopathy of diabetic mice.
    Kidney Int. 2018 May 31. pii: S0085-2538(18)30242.
    >> Share

  88. GROVE KJ, Lareau NM, Voziyan PA, Zeng F, et al
    Imaging mass spectrometry reveals direct albumin fragmentation within the diabetic kidney.
    Kidney Int. 2018 May 17. pii: S0085-2538(18)30202.
    >> Share

    February 2018
  89. HONG Q, Zhang L, Das B, Li Z, et al
    Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury.
    Kidney Int. 2018 Feb 22. pii: S0085-2538(18)30033.
    >> Share

  90. KOPP C, Linz P, Maier C, Wabel P, et al
    Elevated tissue sodium deposition in patients with type 2 diabetes on hemodialysis detected by (23)Na magnetic resonance imaging.
    Kidney Int. 2018 Feb 15. pii: S0085-2538(17)30857.
    >> Share

  91. NOWAK N, Skupien J, Smiles AM, Yamanouchi M, et al
    Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development.
    Kidney Int. 2018 Feb 2. pii: S0085-2538(17)30892.
    >> Share

  92. PERCO P, Mayer G
    Molecular, histological, and clinical phenotyping of diabetic nephropathy: valuable complementary information?
    Kidney Int. 2018;93:308-310.
    >> Share

    January 2018

  93. Zhang L, Zhang Q, Liu S, et al. DNA methyltransferase 1 may be a therapy target for attenuating diabetic nephropathy and podocyte injury. Kidney Int. 2017;92:140-153.
    Kidney Int. 2018;93:271.
    >> Share

    December 2017
  94. XIE Y, Bowe B, Li T, Xian H, et al
    Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus.
    Kidney Int. 2017 Dec 7. pii: S0085-2538(17)30676.
    >> Share

    October 2017
  95. NAIR V, Komorowsky CV, Weil EJ, Yee B, et al
    A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome.
    Kidney Int. 2017 Oct 18. pii: S0085-2538(17)30610.
    >> Share

  96. CHUN N, Wyatt CM, He JC
    Identification of a protective proteomic signature and a potential therapeutic target in diabetic nephropathy.
    Kidney Int. 2017;92:780-781.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016